Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Valneva
Biotech
Pfizer, Valneva show Lyme disease shot effective for 2nd booster
The immune responses of VLA15 when assessed a month after the second booster “were similar to those reported after receiving the first booster dose.”
James Waldron
Sep 3, 2024 4:30am
Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine
Aug 1, 2024 8:26am
Valneva sells priority review voucher for $103M, R&D to benefit
Feb 5, 2024 9:15am
Pfizer, Valneva overcome CRO Lyme disease recruitment problems
Dec 5, 2023 3:20pm
Pfizer links Lyme booster to phase 2 pediatric antibody response
Sep 7, 2023 7:30am
Pfizer cuts enrollment for Lyme disease trial after CRO debacle
Aug 22, 2023 1:00pm
